NEUP · Neuphoria Therapeutics Inc
United States · RS rating 20 · As of 2026-11-03
| Price | 2.99 USD |
|---|---|
| 1-day change | -1.6% |
| RS rating (overall / 1M / 3M / 12M) | 20 / 30 / 26 / 29 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 25 / 8 / 38 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +82.5% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +45.4% |
| Market cap (USD) | $26.5M |